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Abstract
Background: Better tools are required for the earlier identification and management of orofacial pain with different
aetiologies. The painDETECT questionnaire is a patient-completed screening tool with utility for identification of
neuropathic pain in a range of contexts. 254 patients, referred from primary care for management of orofacial pain
and attending a secondary care centre, were prospectively recruited, and completed the painDETECT prior to
consultation. The aim of this study was to determine the accuracy of the painDETECT to detect neuropathic
components of orofacial pain, when compared to a reference standard of clinical diagnosis by experienced physicians,
in a cohort of hospital-based patients.
Results: For the 251 patients included in the analysis, the painDETECT had a modest ability to detect neuropathic
components of orofacial pain (AUROC, 0.63; 95% CI, 0.58–0.70; p = 0.001). Patients with orofacial pain diagnoses
associated with neuropathic components had higher painDETECT scores than those with non-neuropathic
components. However, the painDETECT was weaker at distinguishing patients with mixed pain types, and
multiple diagnoses were associated with poor accuracy of the painDETECT.
Conclusion: In secondary care settings, the painDETECT performed modestly at identifying neuropathic components,
and underestimates the complexity of orofacial pain in its mixed presentations and with multiple diagnoses. Prior to
clinical applications or research use, the painDETECT and other generic screening tools must be adapted and revalidated
for orofacial pain patients, and separately in primary care, where orofacial pain is considerably less common.
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Introduction
Accurate diagnosis of orofacial pain (OFP) is essential
for appropriate patient management in primary and sec-
ondary care. Acquisition of a detailed pain history and
examination directs diagnoses and treatment [1]. How-
ever, diagnosis of OFP is complex. Certain types of OFP
are musculoskeletal in origin, such as temporomandibu-
lar disorders (TMD), others are neuropathic, such as tri-
geminal neuralgia (TN) and nerve injury-post dental
extraction, whereas some have an unknown aetiology,
such as chronic (persistent) idiopathic facial pain (CIFP).
Mixed pain syndromes may also exist, where, rather
than a binary distinction, pain may exist on a continuum
of ‘more or less neuropathic’ [2, 3]. Due to a limited un-
derstanding of the pathophysiology of these processes,
and the possibility of multiple OFP diagnoses occurring
within the same patient, misdiagnosis and inappropriate
referral of these patients is common, particularly for
non-specialist clinicians [4, 5]. The management of mus-
culoskeletal compared to neuropathic origin varies. For
example, though commonly prescribed in primary and
secondary care, non-steroidal anti-inflammatory medica-
tions are not recommended for neuropathic pain [6].
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Moreover, the management of neuropathic pain is chal-
lenging, as patients are frequently unresponsive to drug
treatment [7]. Earlier recognition and distinction of the
aetiology of OFP in patients is needed, particularly due
to the substantial patient burden and interference with
daily living that some diagnoses may have [8].
Patient-completed screening questionnaires may sup-
plement the recognition and clinical diagnosis of OFP in
a variety of settings. These are paper-based or electronic
tools that are easily administered to patients. In differen-
tiating between common dental conditions and un-
known OFP diagnoses [9], screening questionnaires may
be useful for the earlier triaging of OFP patients to ap-
propriate secondary or tertiary care pathways. However,
it is important that these tools are validated for use in
different settings, including primary or secondary care
and epidemiological surveys. Such screening question-
naires may also be available to patients to complete and
score over the internet, with no input from health care
professionals, which adds to the importance of deter-
mining if they can accurately recognise different OFP
diagnoses.
One such tool developed in 2006, the painDETECT
screening questionnaire (PD-Q), uses a scoring method
between − 1 and 38 to estimate the likelihood of a neuro-
pathic pain component in patients. The PD-Q was origin-
ally designed to identify neuropathic components in back
pain [10]. Since its conception, the PD-Q has been vali-
dated and translated into multiple languages, it is easy for
patients to use, and has been shown to identify neuro-
pathic pain components in different contexts, including
lower back pain, arthritis, fibromyalgia, thoracotomy and
malignancy [11]. Compared to other screening tools for
neuropathic pain, the PD-Q does not require clinical
examination, inquires about pain evoked by mild pressure
and heat or cold [12] and thus has the potential to be used
as a rapid pre-consultation tool to differentiate between
aetiologies of OFP. To date, the PD-Q has been tested in
populations of patients with specific OFP diagnoses. Elias
and colleagues found that 34% of patients with
post-traumatic trigeminal nerve injury at their centre ob-
tained a PD-Q score of at least 19 [13]. More recently,
Heo and colleagues applied the PD-Q to patients with
burning mouth syndrome (BMS), and found a low sensi-
tivity and high specificity for the identification of neuro-
pathic pain components in this population [14]. Testing
the PD-Q across a broad range of facial pain diagnoses is
required to determine whether this tool would have utility
as a screening tool for neuropathic pain in OFP. Our
centre receives a heterogeneous group of patients with
OFP [5], providing an opportunity to assess the PD-Q in a
secondary care setting. The aim of this study was to deter-
mine the utility of the PD-Q to detect neuropathic pain in
a hospital-based cohort of patients with OFP.
Methods
Design and setting
Given its diagnostic nature, this prospective, single-centre
cohort study was conducted in concordance with the lat-
est version of the STARD checklist for reporting studies of
diagnostic accuracy [15]. Ethical approval was gained for
the study from the South East London REC 3 Proportion-
ate Review Sub Committee (Reference: 10/H0808/84).
Patients were recruited at a London academic facial pain
centre, which sees over 700 new patients a year, referred
by primary care practitioners or specialists and in the oral
surgery unit [5]. Prior to their appointment at our centre,
patients routinely complete a series of questionnaires [16].
Participants
Recruitment was conducted by three specialty dentists be-
tween 2010 and 2015, each completing their postgraduate
studies. During the project phase of the dentists’ post-
graduate studies, all patients referred from primary care,
and attending OFP clinics and one oral surgery clinic,
were consecutively recruited. Participants were excluded
from the study if they: were below 18 years of age at con-
sultation, had declined participation, were unable to
complete the questionnaire without assistance. Partici-
pants with acute pain and those with more than one OFP
diagnosis were recruited. From each participant, the fol-
lowing characteristics were planned, prior to PD-Q com-
pletion or consultation, and collected for each participant:
age in years, gender, any secondary clinical diagnoses and
the presence of anxiety or depression based on Hospital
Anxiety and Depression Scale scores [17].
Test methods
Participants completed a paper-based copy of the PD-Q
prior to their consultation with the clinician. The ques-
tionnaires were collected by the specialty dentists, and
not shown to the assessing clinicians. Uncompleted
questionnaires were returned to the patient before con-
sultation to encourage completion, but questionnaires
remaining incomplete were excluded from analyses. The
clinical diagnosis of each patient, serving as the refer-
ence standard of diagnosis, was obtained after a full as-
sessment by an expert in pain medicine by means of a
consultation, with a detailed pain history and clinical
examination. Secondary diagnoses, classified as either
orofacial pain or an alternative pre-existing non-
orofacial diagnosis, were assigned to patient if necessary,
but the primary diagnosis was classified as the predom-
inant pain experienced. An independent clinician
reviewed the initial diagnoses and confirmed these after
initiation of a management plan. Clinical diagnosis was
selected as a reference test, as it is presently the gold
standard for diagnosis; based on the requirement of a
detailed pain history and examination for differential
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diagnosis of OFP [18]. Clinical diagnoses were then
grouped according to The International Classification of
Headache Disorders [19], with a separate and specific
classification applied for TMD [20]. Prior to analysis,
clinical diagnoses were grouped into predominantly
neuropathic, pain of a mixed aetiology with both neuro-
pathic and non-neuropathic components, or
non-neuropathic. At this stage, participants with a diag-
nosis not confirmed by an independent clinician were
excluded from analysis.
The completed questionnaires were scored according
to the methodology described in the original reports of
the PD-Q [10]. Cut-offs were applied for analysis of the
PD-Q as previously described. A PD-Q score ≤ 12 indi-
cates a neuropathic component is not likely, whereas a
score ≥ 19 indicates that a neuropathic component is
likely. Between PD-Q scores of 12 and 19, neuropathic
pain can be present, but is uncertain. Cut-offs were not
applicable for the reference standard of clinical diagno-
sis. As the questionnaires were completed by each par-
ticipant prior to consultation, clinicians were blinded to
the results of the index test. Independent study investi-
gators received clinical information, the results of the
index test and reference standard.
Analysis and statistics
As a previous study found the PD-Q to have an AUC of
approximately 0.8 to distinguish BMS from nociceptive
pain [14], it was anticipated that the PD-Q would have
an accuracy of 80%, and it is required to estimate this
figure to within 5% of the true population value. With a
95% confidence interval (CI), it was calculated that 246
patients were required for the study. The primary out-
come of the study was the accuracy of the PD-Q for rec-
ognition of neuropathic pain components, compared
with clinical diagnosis made by senior staff. This was de-
termined using: sensitivity, specificity, predictive values,
and receiver operating characteristics (ROC). For ROC
analysis, the ‘test’ state was defined as patients with
neuropathic pain or pain of mixed aetiology, whereas pa-
tients with non-neuropathic pain served as the ‘control’
state. ROC curves were drawn and the area under the
curve (AUC) was calculated. The accuracy of the PD-Q
was further analysed by comparing the PD-Q scores for
patients with neuropathic, non-neuropathic or mixed
pain using a Kruskal-Wallis test. Where a significant dif-
ference in PD-Q was observed across diagnoses, pairwise
multiple comparisons with Bonferroni correction were
used to calculate adjusted p values between individual
diagnoses. The secondary outcome of the study related
to factors influencing correct diagnosis of the PD-Q.
This included determining Pearson’s correlation
co-efficient (r) between PD-Q scores and each patient
characteristic, and a stepwise multivariate logistic
regression to independently determine the adjusted ef-
fect (using normalised β values) of each patient charac-
teristic and PD-Q scores.
All continuous variables, where parametric, are pre-
sented as means with standard deviations (SD), and where
non-parametric, are presented as medians with interquar-
tile range (IQR). Categorical variables are presented nu-
merically and as a percentage of the sample. p values less
than or equal to 0.05 were considered statistically signifi-
cant. 95% CIs were applied to all continuous outcomes,
and percentages were calculated for categorical outcomes.
All data were managed, analysed and graphed using IBM
SPSS Statistics for Macintosh, Version 25.0 (IBM Corp.,
Armond, NY) and Prism for Macintosh, Version 7
(GraphPad Software Inc., San Diego, CA).
Results
Participants and characteristics
254 participants attended the facial pain clinic during re-
cruitment periods between 2010 and 2015, and were
given the PD-Q to complete prior to their appointment
with the clinician (Fig. 1). All participants were subse-
quently seen by the facial pain team, who took the his-
tory and performed the examination to ascertain the
clinical diagnosis. From the 254 patients, one patient
was excluded due to non-completion of the question-
naire. From the remaining 253 patients, a further two
were excluded due to discrepancy in the clinical diagno-
sis. Therefore, 251 out of 254 (98.8%) of patients were
included in the analysis. Patient characteristics are pre-
sented in Table 1, stratified by the aetiology of OFP. The
overall characteristics of the cohort of 251 participants
were as follows: mean age, 47.3 (SD, 15.7); proportion of
females, 191/251 (76.1%); proportion with a secondary
diagnosis, 74/251 (29.4%, see Additional file 1: Table S1)
and proportion with anxiety or depression, 48/250
(19.2%). The numbers of patients for each clinical diag-
nosis are shown in Table 2.
Accuracy of the PD-Q for recognition of neuropathic pain
components in orofacial pain
The PD-Q scores were calculated for each of the 251
participants, stratified by neuropathic, non-neuropathic
or mixed aetiology. There was minimal time between ad-
ministration of the PD-Q and subsequent appointment
with a clinician. No participants experienced adverse
events during the study period.
ROC curve analysis was performed to determine the
accuracy of the PD-Q in detection of neuropathic pain
components. The AUC was calculated and compared to
an identity line, with an area of 0.50, and sensitivities
and specificities were derived for each cut-off of the
PD-Q (Fig. 2). The AUC of the PD-Q was significantly
higher than that of the identity line (AUC, 0.63; 95% CI,
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0.58–0.70; p = 0.001). Our statistical model derived sen-
sitivities and specificities corresponding to the PD-Q
scores, and predictive values were calculated from these,
given the prevalence of neuropathic or non-neuropathic
pain within the patient cohort. At a cut-off of 11.5, given
a prevalence of 54.6% patients without neuropathic pain
components in the cohort, the PD-Q had a sensitivity of
59.6%, specificity of 56.9%, PPV of 62.4% and NPV of
53.5%. At a cut-off of 19.5, given a prevalence of 45.4%
patients with some neuropathic pain components in the
cohort, the PD-Q had a sensitivity of 28.9%, specificity
of 83.2%, PPV of 58.9% and NPV of 58.5%.
PD-Q scores were compared between the five most
common OFP diagnoses within the cohort, using a
Kruskal-Wallis test (Fig. 3). Overall, there was a
significant difference (p < 0.001) between median PD-Q
scores of patients with neuropathic pain (median, 17.0;
IQR, 10.0–24.0), non-neuropathic pain (median, 11.0;
IQR, 6.0–17.0) or mixed pain (median, 10.0; IQR, 7.0–
17.0) aetiologies of OFP. Pairwise comparisons revealed
statistically significant differences in median PD-Q score
between neuropathic and non-neuropathic pain (p <
0.001) and between neuropathic and mixed pain (p
= 0.008), but not between non-neuropathic and mixed pain
(p > 0.5). The median PD-Q scores for the 12 most com-
mon clinical diagnoses, containing five or more patients
per group and accounting for 212/251 (84.5%) of the co-
hort, are shown in Table 3.
Patient factors associated with PD-Q score in orofacial pain
We performed a multivariate linear regression to deter-
mine whether any of the patient characteristics includ-
ing: age, gender, secondary diagnosis or presence of
anxiety or depression had an influence on the PD-Q
score independently. There was a significant correlation
between the PD-Q score and a secondary diagnosis
(r = − 0.20; p = 0.001) and also anxiety or depres-
sion (r = − 0.15; p = 0.009). However, when adjusted
in the regression model, only a secondary diagnosis
contributed significantly to the PD-Q score (β = − 0.18;
p = 0.006) when adjusted for patient age, gender and
presence of anxiety or depression. Anxiety or depression,
when adjusted for other patient characteristics, did not
reach significance (β = − 0.12; p = 0.055).
Fig. 1 Participant flow diagram. One patient who did not complete the questionnaire had difficulty reading the questionnaire. The two patients
with unclear clinical diagnoses were categorised as having orofacial pain of mixed aetiology







Mean age in years (± SD) 54.0 ± 13.1 42.6 ± 15.6 51.1 ± 15.0
Female (%) 51 (70.8) 107 (78.1) 33 (78.6)
Secondary clinical
diagnosis (%)
23 (31.9) 34 (24.8) 17 (40.5)
Anxiety or depressiona (%) 12 (16.7) 29 (21.2) 7 (16.7)
Anxiety only 5 12 6
Depression only 5 10 0
Both anxiety and depression 2 7 1
a: Anxiety or depression as determined by HADS scores
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Table 2 Classification and frequency of OFP diagnoses
Neuropathic (n) Non-neuropathic (n) Mixed pain (n)
Trigeminal neuralgia (27) Temporomandibular disorder (88) Atypical odontalgia (20)
Trigeminal neuropathic pain (22) Pericoronitis (8)a Chronic idiopathic facial pain (13)
Burning mouth syndrome (6) Psychosomatic pain (8) Chronic post-dental treatment (6)
Trigeminal neuralgia with concomitant pain (5) Migraine (5) Post-radiotherapy (1)
Short unilateral neuralgiform headache attacks
with autonomic features (5)
Pulpitis (4)a Post-stroke (1)
Short-lasting unilateral neuralgiform headache
with conjunctival injection and tearing (1)
Post-herpetic neuralgia (2)
Acute post-dental treatment (3)a Post-brain surgery (1)
Hemicrania continua (2) Unspecified muscular (3)
Periodontitis (3)a
Neuropathic post-trauma (1) Tension headache (2)
Facial pain with multiple sclerosis (1) Hypervigilance (2)
Tumour-associated neuropathic (1) Temporal arteritis (1)







Insertion of dental implant (1)a
Fibromyalgia (1)
a: Pain is dental in origin
Fig. 2 AUROC analysis of the PD-Q for detecting neuropathic pain components in the cohort. The AUC is compared to that of an identity line,
with an area of 0.5. The difference in areas between the curve and the identity line was significant (p = 0.001)
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Discussion
This prospective study tested the accuracy of the PD-Q in
identifying neuropathic pain components in a
hospital-based cohort, with a broad range of orofacial pain
diagnoses. At the PD-Q score above which neuropathic
components are likely, the PD-Q had a low sensitivity and
high specificity. Conversely, at the lower PD-Q cut-off, the
PD-Q has a modest sensitivity and specificity. The PPVs
and NPVs were modest at both cut-offs, indicating a rea-
sonable likelihood that patients with a score above 19
would have a neuropathic pain component, and that
patients with a score below 12 would not. PD-Q scores
were significantly different between clear neuropathic
OFP diagnoses, such as TN or TNP, compared to
non-neuropathic diagnoses, such as TMD, whereas mixed
diagnoses such as CIFP were more ambiguous. Together,
these data suggest that the PD-Q identifies neuropathic
components when clear-cut, but unsurprisingly, performs
less well in patients with a complex, mixed diagnosis, par-
ticularly when multiple diagnoses are present.
Previous studies have examined the utility of the
PD-Q for OFP diagnoses in tertiary centres, and suggest
the PD-Q may not be an appropriate tool in this context.
Elias and colleagues found that only 34% of patients with
post-traumatic trigeminal nerve injury obtained a PD-Q
score of at least 19 [13]. Heo and colleagues applied the
PD-Q to patients with BMS, and found a low sensitivity
(16.7%) and high specificity (97.4%) at a cut-off of 19
[14]. These studies, with smaller sample sizes, include
patients with predominantly neuropathic pain, and their
findings may reflect the low sensitivity of the PD-Q at the
higher cut-off value in the present study. In contrast, our
ROC analysis suggested that the PD-Q has potential for
recognition of neuropathic pain in this hospital-based
cohort, likely because our patient population is more
heterogeneous and representative of secondary care.
Unlike other questionnaires for neuropathic pain, the
PD-Q does not involve clinical examination. Such examin-
ation, including changes in sensory perception, is critical
for making a diagnosis of a neuropathic pain [12]. The
PD-Q was originally designed to identify neuropathic
components in lower back pain [10]. Though response
rates in this study reflect the ease of completing the ques-
tionnaire, the design of the PD-Q makes it difficult for
patients to highlight and draw areas where pain predomi-
nates and radiates to, particularly considering as the size
of the head is very small in the figure within the PD-Q.
Questions in the PD-Q referring to possible pain triggers
do not account for specific face pain triggers such as
washing the face, showering compared to bathing, or the
cold wind; all of which are clues towards orofacial pain of
a neuropathic aetiology, such as classic TN [21].
Despite the strengths of this study, including its pro-
spective nature, blinding of the clinician to the
questionnaire results and the confirmation of the refer-
ence standard of clinical diagnosis by an independent clin-
ician, our data should be interpreted with caution. Firstly,
the study was conducted in a secondary care centre, re-
ceiving population of orofacial pain patients not represen-
tative of primary care or non-specialist settings. Data
previously published from this centre indicated that up to
46% of the patients seen have a diagnosis of TMD [5],
whereas its estimated prevalence in the general population
is between 2 and 6% in developed countries [22]. Given
this prevalence, the rarity of conditions such as TMD and
TN would make a prospective study in primary care ex-
tremely challenging. Another difficulty in translating these
results to primary care is the possibility of changes to the
way the questionnaire is filled out in different settings. In
different settings, patients may rate their pain variably,
dependent on their expectations and desired outcomes of
their consultation. Other factors differ between centres,
such as the person administering the measure, be they
clinician, family member or study investigator. Moreover,
only a small number of patients with acute dental pain
were recruited, which contrasts with primary dental care
in which acute dental pain is predominant. However, the
inclusion of these patients demonstrated that acute dental
pain is not classified as neuropathic, and demonstrate that
patients who score highly in primary dental care should
be referred to a specialist centre for appropriate manage-
ment of neuropathic pain. A second limitation is the diffi-
culty in accommodating for the large proportion of
patients in each group with a secondary diagnosis. This is
representative of the complexity of orofacial pain presen-
tations, and considerably influences the ability of the
PD-Q to accurately identify OFP aetiology, independent of
other patient factors, but likely influences non-adjusted
analyses. To accommodate for this, study clinicians made
a primary diagnosis based on patient history and examin-
ation, to determine the predominant type of pain. The
study is further limited by characteristics not recorded,
such as the pain intensity or educational level of patients,
both of which could influence PD-Q scores. Though pa-
tients were recruited consecutively over individual study
periods, the nature of the study, namely the periods of
time during which patients were not recruited due to ab-
sence of postgraduate students, may have introduced se-
lection bias to the sample. Re-test validity was not
included in this study. Finally, the clinician confirming the
diagnosis, though independent, was not blinded to diag-
nosis made at first consultation, and may be biased by
this information or by treatment response. The time
between diagnosis made at first consultation and inde-
pendent confirmation was not recorded.
The accuracy of the PD-Q is only one of the consider-
ations when determining a screening tool for OFP. The
PD-Q appears a valid tool, in its effectiveness in
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Fig. 3 Scatterplot representing median PD-Q scores for each type of pain in the OFP cohort. Error bars indicate IQR. Brackets and asterisks
represent statistically significant differences between median PD-Q scores. *: p < 0.05, **: p < 0.01
Table 3 painDETECT scores grouped by clinical diagnosis
Type of pain Clinical diagnosis n Median painDETECT score IQR
Neuropathic Trigeminal neuralgia 27 17.0 11.0–21.0
Trigeminal neuropathic pain 21 17.0 10.0–26.5
Burning mouth syndrome 6 9.5 8.3–16.8
Trigeminal neuralgia with concomitant pain 5 17.0 8.0–18.0
Short unilateral neuralgiform headache attacks with autonomic features 5 27.0 25.0–31.0
Non-neuropathic Temporomandibular disorder 88 10.5 5.0–17.0
Pericoronitis 8 11.0 10.3–14.0
Psychosomatic 8 17.5 6.8–21.0
Migraine 5 12.0 3.0–21.0
Mixed Atypical odontalgia 20 8.0 5.3–14.0
Chronic idiopathic facial pain 13 16.0 8.5–18.0
Chronic post-dental treatment 6 12.5 5.3–24.0
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distinguishing neuropathic from non-neuropathic pain
in other contexts [11], the continuous score of the PD-Q
reflecting the spectrum of neuropathic pain presenta-
tions [3] and its availability and validation in different
languages. What has not been compared is the ultimate
treatment and outcome of patients and how these relate
to the initial PD-Q scores, which could be considered its
criterion validity. Moreover, the reliability of the PD-Q
in patients with OFP needs to be ascertained prior to its
implementation in practice. Preliminary data at our
centre indicates a strong concordance in PD-Q score be-
fore and after consultation with a facial pain clinician,
but larger sample sizes are needed to validate this. The
utility and performance of the PD-Q could also be com-
pared to other screening tools for neuropathic pain [12],
and more specific screening tools for OFP diagnoses,
such as those available for TMD and TN [23, 24]. Fi-
nally, the differences between settings prompt a revalid-
ation of the PD-Q in primary care [25], given the
considerably lower prevalence of specific OFP diagnoses
in general clinical and dental practice.
Conclusions
Patient-completed screening tools, such the PD-Q, have
promise in both primary care and hospital practice,
given their ease of use, high completion rate and the po-
tential to aid the triaging of patients with OFP prior to
consultation. Such tools may help to identify patients in
primary care who need a specialist referral, those in den-
tistry who have a non-odontogenic origin of their pain
or may help to inform clinicians as to the aetiology of
pain to make earlier decisions about management and
therapy. However, the PD-Q performed modestly in our
centre given the complexity of presentation and as many
patients have more than one co-existing diagnosis. Prior
to clinical and further research applications, the PD-Q
must be adapted and revalidated for orofacial pain pa-
tients, and separately in primary care, where orofacial
pain is considerably less common. Ultimately, either
patient-completed screening tools should only be imple-
mented within settings they were designed, or
pre-existing general screening tools needs to be opti-
mised in different settings to reflect the variety of clin-
ical situations for which such tools may be applicable.
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